About Gamma-aminobutyric acid receptor subunit delta
Gamma-aminobutyric acid receptor subunit delta (GABRD) is a protein
from Homo sapiens identified by UniProt accession
O14764, 452 residues long.
MolForge cross-references it against 0 known binders and
300 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit delta |
| UniProt accession | O14764 |
| Gene | GABRD |
| Organism | Homo sapiens |
| Length | 452 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (300)
Diseases linked to this target (Open Targets).
- Generalized epilepsy with febrile seizures-plus · score 0.71
- Seizure · score 0.61
- epilepsy · score 0.61
- pain · score 0.60
- migraine disorder · score 0.60
- alcohol dependence · score 0.59
- delirium · score 0.59
- obesity · score 0.58
- coronary artery disease · score 0.58
- Agitation · score 0.57
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14764-F1 | alphafold | PREDICTED | 79.16 | — |
Amino-acid sequence (452 residues)
MDAPARLLAP LLLLCAQQLR GTRAMNDIGD YVGSNLEISW LPNLDGLIAG YARNFRPGIG GPPVNVALAL EVASIDHISE ANMEYTMTVF LHQSWRDSRL SYNHTNETLG LDSRFVDKLW LPDTFIVNAK SAWFHDVTVE NKLIRLQPDG VILYSIRITS TVACDMDLAK YPMDEQECML DLESYGYSSE DIVYYWSESQ EHIHGLDKLQ LAQFTITSYR FTTELMNFKS AGQFPRLSLH FHLRRNRGVY IIQSYMPSVL LVAMSWVSFW ISQAAVPARV SLGITTVLTM TTLMVSARSS LPRASAIKAL DVYFWICYVF VFAALVEYAF AHFNADYRKK QKAKVKVSRP RAEMDVRNAI VLFSLSAAGV TQELAISRRQ RRVPGNLMGS YRSVGVETGE TKKEGAARSG GQGGIRARLR PIDADTIDIY ARAVFPAAFA AVNVIYWAAY AM
Explore Gamma-aminobutyric acid receptor subunit delta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets